PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBleomycin
Bleomycin
Bleomycin (bleomycin) is a small molecule pharmaceutical. Bleomycin was first approved as Blenoxane on 1982-01-01. It is used to treat choriocarcinoma, hodgkin disease, melanoma, non-hodgkin lymphoma, and sarcoma amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
immune system diseasesD007154
Trade Name
FDA
EMA
Bleomycin (discontinued: Blenoxane, Bleomycin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bleomycin sulfate
Tradename
Company
Number
Date
Products
BLENOXANEBristol Myers SquibbN-050443 DISCN1982-01-01
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bleomycinANDA2024-10-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-hodgkin lymphoma—D008228C85.9
sarcoma—D012509—
hodgkin disease—D006689C81
melanoma—D008545—
squamous cell carcinoma—D002294—
testicular neoplasms—D013736C62
choriocarcinoma—D002822C58
teratocarcinoma—D018243—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01D: Cytotoxic antibiotics and related substances
— L01DC: Other cytotoxic antibiotics in atc
— L01DC01: Bleomycin
HCPCS
Code
Description
J9040
Injection, bleomycin sulfate, 15 units
Clinical
Clinical Trials
221 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C80—1———1
Hodgkin diseaseD006689—C81—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBleomycin
INNbleomycin
Description
Bleomycin A2 is a bleomycin. It has a role as an antineoplastic agent and a metabolite.
Classification
Small molecule
Drug classantibiotics (Streptomyces strain)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1
Identifiers
PDB—
CAS-ID11056-06-7
RxCUI1622
ChEMBL IDCHEMBL403664
ChEBI ID3139
PubChem CID5460769
DrugBankDB00290
UNII ID40S1VHN69B (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 53,836 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bleomycin
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
10,142 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use